Sobi™ initiates disclosure of payments to the healthcare industry to increase transparency
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announced that the company has started implementing the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code to make all payments and transfers of value to healthcare professionals and organisations from 2015 publicly available, including sponsorships to attend meetings, speaker fees, consultancy and advisory boards. The information will be made available on Sobi´s corporate web site, starting 31 May 2016.
The implementation of the EFPIA Disclosure Code is an important part of Sobi´s quality work, to meet the high integrity standards that patients, prescribers, budget holders and other stakeholders expect. In the rare disease community collaboration between authorities, healthcare professionals, companies and patient organisations has always been a cornerstone in the development of new and better treatments. Increased transparency will provide an even stronger basis for continued collaboration and can positively impact the quality of research, development and manufacturing across the industry.
“Implementing the EFPIA disclosure code is an integral part of our quality work and an important initiative to build trust for and within our industry,” said Lars Dreiøe, SVP, Chief Quality and Compliance Officer at Sobi. “However, being compliant is the bare minimum. Dialogue and interaction between healthcare professionals and organisations is vital when it comes to building sustainable value to rare disease patients and rare disease communities around the world.”
About EFPIA Disclosure Code
The EFPIA (European Federation of Pharmaceutical Industries and Associations) Disclosure Code is a formal code of conduct that requires all EFPIA member companies and companies which are members of EFPIA member associations to disclose transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs). Under the Code, EFPIA member companies will have to disclose the names of healthcare professionals and organisations that have received payments or other transfers of value from them. They will also have to disclose – by HCP or HCO – the total amounts of value transferred, by type of transfer or value which could consist of, for instance, a grant to an HCO, a consultancy fee for speaking, payment for travel, or registration fees to attend a medical education congress. This information will be published on a public platform, which could be on the company’s own website or a central platform combing data from different companies.
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com or www.sobi.com/report2015.
For more information please contact
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|+46 70 410 71 80||+1 347-224-0819, +1 212-579-0506, +46 8 697 2135|